Definiens Appoints Dr. Gerald Möller as Chairman of its Supervisory Board
Definiens AG, the leader in image analysis for Digital Pathology, today announced that Dr. Gerald Möller, has joined the company's supervisory board as an independent member and has been appointed chairman.
Munich, Germany, November 15, 2012 / B3C newswire / - Definiens AG, the leader in image analysis for Digital Pathology, today announced that Dr. Gerald Möller, has joined the company's supervisory board as an independent member and has been appointed chairman. Following the recent financing round, Dr. Möller will guide the expansion of Definiens' current business and the development and commercialization of innovative products for clinical Digital Pathology.
Definiens' image analysis solutions are currently deployed by all major biopharmaceutical companies, leading cancer centers and key pathology reference labs. Building on the leadership position in the life sciences sector, Definiens is rapidly growing its footprint in tissue based diagnostics, including the development of new companion diagnostic tests. These novel companion diagnostic tests will further accelerate the growth of Definiens' business in Clinical Digital Pathology.
"I am very excited to join Definiens' supervisory board at this defining point in time," commented Gerald Möller. "Quantitative Digital Pathology will not be possible without image analysis as provided by Definiens. I am very much looking forward to working with the Definiens team to further expand the leadership position in image analysis for Digital Pathology and grow the business in companion diagnostics and Clinical Digital Pathology."
Previously, Dr. Möller spent 23 years at Boehringer Mannheim in Germany, Japan and the US, where he held a number of leadership positions, including president of Decentralized Diagnostics, president of Advanced Diagnostics and Biochemicals, and CEO of Boehringer Mannheim Therapeutics. In 1995 he became CEO of the worldwide Boehringer Mannheim Group. Following the company's acquisition by Roche, Dr. Möller became head of Global Development and Strategic Marketing, Pharmaceuticals, and a member of the Executive Committee at Hoffmann LaRoche. In addition to Definiens, Dr. Möller is chairman of the board at Morphosys AG and sits on several further life sciences and diagnostics boards, including Illumina Inc., Bionostics Inc., and Vivacta Ltd. He also is chairman of the Foundation for Innovative New Diagnostics (FIND), a product development and implementation partnership financed in part by the Bill & Melinda Gates Foundation. He holds a Ph.D. in physical chemistry from the University of Kiel in Germany.
"We are delighted to have Dr. Möller as chairman of our board of directors. Gerald's strong track record in the healthcare space and his unmatched expertise in advanced diagnostics will be invaluable as Definiens expands into Clinical Digital Pathology," said Thomas Heydler, CEO of Definiens. "His commitment and vision will be instrumental to further strengthen Definiens as the leader in Quantitative Digital Pathology for life science research, tissue based companion diagnostics and clinical routine."
Related News
-
News Women in Pharma: Hiring Across the Gender Divide
In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News Revolutionising cancer treatment with mRNA-based therapeutics
Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours. -
News Breaking Barriers: Innovations in Oral Solid Dose Form Bioavailability
The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ... -
News Choosing the Right CDMO Partner: A Comprehensive Guide
Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance